Axsome Therapeutics AXSM Finance Lease Liabilities (Total)
Finance Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiability.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's finance lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Axsome Therapeutics's finance lease liabilities (total)?
- Axsome Therapeutics (AXSM) reported finance lease liabilities (total) of $9.04M in Q1 2026.
- How has Axsome Therapeutics's finance lease liabilities (total) changed year-over-year?
- Axsome Therapeutics's finance lease liabilities (total) increased by 64.4% year-over-year, from $5.5M to $9.04M.
- What does finance lease liabilities (total) mean?
- The total long-term debt obligation resulting from finance leases.
- How do you interpret finance lease liabilities (total)?
- High levels indicate significant reliance on leased assets for operations, impacting long-term cash flow.
- How does finance lease liabilities (total) compare across companies?
- Varies based on the company's strategy of leasing versus owning research facilities and equipment.